# Twelve Month Study of the Safety of Eszopiclone in Adult Subjects With Insomnia

> **NCT01710631** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 791 (actual)

## Conditions studied

- Primary Insomnia

## Interventions

- **DRUG:** eszopiclone 3 mg
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01710631
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-02
- **Primary completion:** 2002-08
- **Final completion:** 2002-08
- **Target enrollment:** 791 (ACTUAL)
- **Last updated:** 2012-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01710631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01710631, "Twelve Month Study of the Safety of Eszopiclone in Adult Subjects With Insomnia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01710631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*